[(2R)-1-[[3-[2-[2-[[2-(2-hydroxybenzoyl)oxybenzoyl]amino]ethyldisulfanyl]ethylamino]-3-oxopropyl]amino]-3,3-dimethyl-4-[(5Z,7E,10Z,13Z,16Z)-nonadeca-5,7,10,13,16-pentaenoyl]oxy-1-oxobutan-2-yl] pyridine-3-carboxylate

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 缩酚酸和缩酚酸环醚类
• 英文名称: [(2R)-1-[[3-[2-[2-[[2-(2-hydroxybenzoyl)oxybenzoyl]amino]ethyldisulfanyl]ethylamino]-3-oxopropyl]amino]-3,3-dimethyl-4-[(5Z,7E,10Z,13Z,16Z)-nonadeca-5,7,10,13,16-pentaenoyl]oxy-1-oxobutan-2-yl] pyridine-3-carboxylate
• 化学式: C₅₂H₆₄N₄O₁₀S₂
• 分子量: 969.2
• InChiKey: GNOSVBLMDFHJKS-HYWCTVSMSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  9.2
• 重原子数：
  68
• 可旋转键数：
  34
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.37
• 拓扑面积：
  250
• 氢给体数：
  4
• 氢受体数：
  13

文献信息

• [EN] COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC AND LIPID DISORDERS<br/>[FR] COMPOSITIONS ET MÉTHODES POUR LE TRAITEMENT DE TROUBLES MÉTABOLIQUES ET LIPIDIQUES
  申请人：KANDULA MAHESH

  公开号：WO2014083476A2

  公开（公告）日：2014-06-05

  The invention relates to the compounds of formula I and formula II or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I or formula II; and methods for treating or preventing metabolic and lipid disorders may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of diabetes, insulin resistance, hyperglycemia, hypertriglyceridemia, lipid disorders and cardiovascular diseases.